RxDoctor Payments Data

Marcia Bowden, MD

Internal Medicine · Memphis, TNNPI 1083641252

Payments from drug & device makers

$567in general payments, 2019–2025

Across 17 payments — averaging $33.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$406
  • GSK$81
  • Novartis$19
  • Novo Nordisk$17
  • Pfizer$16
  • Boehringer Ingelheim$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott8$406
GSK4$81
Novartis1$19
Novo Nordisk1$17
Pfizer1$16
Boehringer Ingelheim1$15
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$567 in reported general payments places this provider in the 60th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$56,450
Medicare patients
134
Services billed
912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate33$38,946
LinzessLinaclotide40$30,806
OzempicSemaglutide24$30,498
EliquisApixaban30$29,355
XareltoRivaroxaban16$18,685
JanumetSitagliptin Phos/Metformin Hcl11$18,598
FarxigaDapagliflozin Propanediol20$14,486
MounjaroTirzepatide11$12,676
Amlodipine Besylate431$2,145
Rosuvastatin Calcium149$2,086
Albuterol Sulfate HfaAlbuterol Sulfate62$2,075
Omeprazole116$2,029
Atorvastatin Calcium265$2,028
Potassium Chloride99$1,831
Aspirin-Dipyridamole ErAspirin/Dipyridamole11$1,586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$14$57,54444 claims
Novo NordiskOzempic$17$30,49824 claims
PfizerEliquis$16$29,35530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →